FOXO4-DRI: what the research shows
- By Reed Calder
- Last reviewed Nov 16, 2026
- 26 studies and official documents checked
In short
FOXO4-DRI is a lab-made peptide of 46 amino acids, built from D-amino acids in reverse order (“D-retro-inverso”). It was designed to pull a protein called FOXO4 away from p53 inside senescent “zombie” cells, cells that stopped dividing after damage but don’t die, so that p53 can trigger their death (Baar et al., 2017).
In the 2017 study it neutralized chemotherapy damage in mice and restored fitness, fur density and kidney function in fast-aging and naturally aged mice. Later mouse studies reported less lung scarring and more testosterone in aged males. But in mice prone to pulmonary hypertension it caused loss of lung blood-vessel cells (Born et al., 2023), in a dish it did not single out senescent endometrial stem cells (Deryabin et al., 2022), and in expanded human cartilage cells it removed senescent cells without improving cartilage formation (Huang et al., 2021).
We found no study that gave FOXO4-DRI to people and no registered trial. It isn’t FDA-approved. The FDA’s drug directory has three “FOXO4-DRI” bulk-ingredient listings whose ingredient field names a cat-allergen peptide, and the 2026 WADA list bans unapproved substances under S0.
EvidenceCellAnimalHumanmouse, rat and cell studies; no study in people
You’ll often read that FOXO4-DRI clears “zombie” cells without harming healthy ones, reverses aging, and is in or headed for clinical trials. This page covers what FOXO4-DRI is, what was studied in mice, rats and human cells, the usual claims checked, what the studies used, side effects, where it stands with the FDA and in sport, and what’s still unknown.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| FOXO4-DRI, FOXO4 D-retro-inverso, “FOXO4 peptide” | A synthetic peptide of 46 amino acids, made of D-amino acids in reverse order, with a FOXO4-derived region and a cell-penetrating tail: formula C228H388N86O64, about 5,358 g/mol (PubChem CID 168431240; Baar et al., 2017; Bourgeois et al., 2025) | We found no study |
| Proxofim | A name used for it on Wikipedia and in popular sources. We found no record of it in the FDA’s substance registry | We found no study |
| ES2, CPP-CAND and other FOXO4-p53 peptides | Different peptides designed later to block the same interaction. Their results belong to them, not to FOXO4-DRI (Le et al., 2021; Kang et al., 2025) | We found no study |
| Dasatinib plus quercetin, fisetin, navitoclax (ABT263) | Other “senolytic” drugs and supplements, which work in other ways. Studies of them are not studies of FOXO4-DRI (Born et al., 2023; Alameen et al., 2026) | Covered separately |
| “Senolytic peptide”, “zombie cell clearer” | Descriptions of what it is meant to do. See below for what the studies found (Baar et al., 2017) | See the first row |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The FDA’s substance registry has no FOXO4-DRI record, so the registry here is PubChem.
| Form | CAS number | Registry record |
|---|---|---|
| FOXO4-DRI (a D-amino-acid peptide) | 2460055-10-9 | PubChem |
What FOXO4-DRI is
Senescent cells have stopped dividing after damage and stay in the tissue. The 2017 study found that senescent cells use the protein FOXO4 to hold p53, a protein that can trigger cell death, in the nucleus, which helps keep the cells alive (Baar et al., 2017).
FOXO4-DRI is a peptide designed to disrupt that binding. In the cell experiments it made p53 leave the nucleus and triggered death in senescent cells (Baar et al., 2017; Zhang et al., 2020). The authors chose a stretch of FOXO4 that is the same in people and mice but differs from the related proteins FOXO1 and FOXO3. They built it from D-amino acids in a reversed sequence, a design they say can change a peptide’s chemical properties and may improve its potency (Baar et al., 2017).
A 2025 structural study found that FOXO4-DRI binds a disordered part of p53, called TAD2, and that both its FOXO4-derived region and its cationic cell-penetrating tail contribute to binding (Bourgeois et al., 2025). Binding in a test tube doesn’t show how it behaves in a person.
It is an unapproved lab compound. The 2017 paper says the peptide and the mice are subject to patent applications, and two of its authors co-founded companies that the paper says were not involved: one is a co-founder and shareholder of Unity Pharmaceuticals and the other a co-founder of AgenD (Baar et al., 2017).
What has been studied
We found no study that gave FOXO4-DRI to people. PubMed lists 19 records that mention it (searched November 16, 2026); they are cell, mouse and rat studies, reviews and lab analyses. Studies of other senolytics, such as dasatinib with quercetin, don’t count as evidence for FOXO4-DRI.
In mice: aging, hormones and blood vessels
| Study | Model | What was used | What it found |
|---|---|---|---|
| Baar et al., 2017 | Human lung fibroblasts made senescent by radiation or doxorubicin; mice given doxorubicin; fast-aging Xpd TTD/TTD mice; naturally aged mice (over 110 weeks) | In cells, 25 µM. In mice, 5 mg/kg three times, every other day, into a vein or the abdomen | In senescent cells it pushed p53 out of the nucleus and triggered cell death; low doses were well tolerated in normal cells in the same dish. In mice it neutralized doxorubicin’s weight loss and liver toxicity, and after 30 days kidney markers (blood urea and creatinine), fitness and fur density improved. Heart sections of treated 26-week-old mice showed no apparent abnormalities. The paper reports no lifespan data |
| Zhang et al., 2020 | Human testis tissue (stained, not treated); mouse Leydig cells; male mice aged 20 to 24 months | 5 mg/kg into the abdomen every other day for three doses | Thirty days later testosterone and two testosterone-making proteins were higher; body and testis weight did not change. The authors note FOXO4 is also made in human muscle and placenta and say muscle damage, especially to the heart, needs attention; they could not test it. No conflicts declared |
| Li et al., 2024 | Senescent Leydig cells and naturally aged mice | FOXO4-DRI | Senescent Leydig cells died and released fewer secreted factors; sperm quality and spermatogenesis improved in the aged mice. Not a fertility study |
| Hu et al., 2025 | Naturally aged and D-galactose-aged mice; senescent endothelial cells in a dish | 5 mg/kg into the abdomen every 2 days for 4 weeks to 1 month | The authors report better vascular function and less vascular aging in the aorta, with more cell death in the senescent endothelial cells |
EvidenceCellAnimalHumanmice; small studies; no lifespan test
In animals: lungs
| Study | Model | What was used | What it found |
|---|---|---|---|
| Han et al., 2022 | Mice with bleomycin lung fibrosis; lung fibroblast cell lines | FOXO4-DRI, compared with the approved drug pirfenidone | Fewer senescent cells and less collagen, like pirfenidone. In cells it was more likely to kill myofibroblasts made by TGF-beta than ordinary lung fibroblast lines. the 2024 correction replaces a duplicated image panel in Figure 6B |
| Liu et al., 2023 | Mice with bleomycin lung fibrosis; activated fibroblasts | FOXO4-DRI after the injury | Milder lung damage and less collagen |
| Meng et al., 2021 | Human lung cancer cells with fibroblasts, in nude mice; mice with radiation lung injury | 5 mg/kg into the abdomen on days 1, 3 and 5 of a week, for 2 cycles | Made the tumors more sensitive to 8 Gy of radiation and lowered radiation-induced lung fibrosis. Human patients gave tissue; none was given the peptide |
| Jing et al., 2024 | Rat pups in 95% oxygen, a model of premature-baby lung disease | FOXO4-DRI into the abdomen on days 4, 6, 8 and 10 | Results similar to two other treatments tested: less senescence and better lung air-sac structure. Short-term, in rat pups |
| Born et al., 2023 | Mice and rats with pulmonary hypertension models; lung tissue from patients | FOXO4-DRI or navitoclax (ABT263), and a gene that kills senescent cells | In mice overexpressing the serotonin transporter, FOXO4-DRI or ABT263 was followed by changed lung blood pressure and loss of the cells lining lung blood vessels. The authors conclude that eliminating senescent lung vessel cells “may worsen” lung blood pressure. Several results in the paper came from navitoclax or the gene, not the peptide |
EvidenceCellAnimalHumanmice and rats; benefit in two fibrosis models and harm in a pulmonary hypertension model
In human cells
| Study | Model | What was used | What it found |
|---|---|---|---|
| Huang et al., 2021 | Healthy-donor cartilage cells grown to 3 or 9 doublings | FOXO4-DRI on the cells | It removed more than half of the 9-doubling cells and left the 3-doubling cells alone, and senescence fell. Treated cells did not make better cartilage in a pellet test |
| Kong et al., 2025 | Fibroblasts from keloid scars and from normal skin, made senescent by limiting serum; keloid tissue samples | 25 µM for 3 days | Cell survival fell more in the senescent cells than in non-senescent controls: a 2.7-fold difference for keloid fibroblasts and 1.7-fold for normal skin fibroblasts. Keloid tissue samples showed cell death. No conflicts declared |
| Deryabin et al., 2022 | Human endometrial stem cells made senescent | 25 µM | Neither FOXO4-DRI nor quercetin, nor dasatinib with quercetin, killed the senescent cells more than controls; the senescent cells were equally or more resistant. The paper’s main subject was a different compound, nigericin |
EvidenceCellAnimalHumancells in a dish; no one was given FOXO4-DRI
In cancer cells, and the related peptides
| Study | Model | What was used | What it found |
|---|---|---|---|
| Ning et al., 2026 | Cultured brain tumor (glioma) cells | Temozolomide with FOXO4-DRI | FOXO4-DRI added to the effect of temozolomide by killing the senescent cells. Cells only; a separate 82-patient group in the paper concerned a tumor marker, not the peptide |
| Le et al., 2021 | Human cancer cells; mouse melanoma and aged mice | ES peptides, with FOXO4-DRI as a comparison | The paper’s results are for its own ES peptides, one called ES2, including a survival advantage with a BRAF inhibitor in melanoma mice. They are not FOXO4-DRI results |
| Kang et al., 2025 | Chemotherapy-senescent cancer cells | CPP-CAND, a new peptide, compared with FOXO4-DRI | The authors report high selectivity for CPP-CAND, which has fewer negative charges, a shorter length and a cell-penetrating tail. Cells only |
EvidenceCellAnimalHumancells, plus mice for the ES peptides; no cancer study in people
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| It clears senescent cells without harming healthy ones | Mixed | Mixed. In several cell studies and in mice it picked senescent cells. It failed to do so in endometrial stem cells, and in mice prone to pulmonary hypertension it was followed by loss of lung blood-vessel cells (Baar et al., 2017; Kong et al., 2025; Deryabin et al., 2022; Born et al., 2023) |
| It reverses aging | Untested | Untested. In fast-aging and aged mice it restored fitness, fur density and kidney markers, and we found no lifespan data. No study in people (Baar et al., 2017) |
| It raises testosterone | Untested | Untested. In aged male mice, testosterone was higher 30 days after three doses. The human testis tissue was only stained (Zhang et al., 2020) |
| It treats lung fibrosis | Untested | Untested. Less collagen in two mouse bleomycin models, and in radiation lung injury. In a pulmonary hypertension model it was linked to harm (Han et al., 2022; Liu et al., 2023; Meng et al., 2021; Born et al., 2023) |
| It is safe because it only hits senescent cells | Untested | Untested in people. Heart sections looked normal in the 2017 mice, but the 2020 authors could not test heart and muscle damage, and the pulmonary hypertension study found harm in a mouse model (Baar et al., 2017; Zhang et al., 2020; Born et al., 2023) |
| It helps fight cancer | Untested | Untested. Cultured glioma cells and radiation-treated lung tumors in mice responded when it was added to other treatments. No study in people (Ning et al., 2026; Meng et al., 2021) |
| It reverses brain aging | Untested | Untested. We found no study of FOXO4-DRI in the brain. A review on brain aging discusses other senolytics, and the brain studies behind it that we traced were of dasatinib with quercetin or genetic clearance (Alameen et al., 2026) |
| It has been tested in people | Contradicted | We found none. ClinicalTrials.gov has no record for it, and PubMed lists no study in volunteers (ClinicalTrials.gov search) |
| It is in clinical trials | Contradicted | We found no registered trial. Some social media posts mention one; we found no registry record (ClinicalTrials.gov search) |
| FOXO4-DRI is an FDA-approved drug | Contradicted | No. We found no Drugs@FDA application (openFDA) |
| Research-grade FOXO4-DRI is pure and as described | Untested | We found no published analysis of FOXO4-DRI sold online, so the claim is untested |
| FOXO4-DRI is banned in sport | Mixed | Mixed. The 2026 WADA list doesn’t name it. Its S0 class prohibits any substance with no government approval for human therapeutic use, at all times, and names BPC-157 and DNP as examples (WADA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | What was tested | Amount and route |
|---|---|---|
| Baar et al., 2017 | Doxorubicin damage, fast-aging and aged mice | 5 mg/kg three times, every other day (days 1, 3 and 5), into a vein or the abdomen; senescent cells at 25 µM |
| Zhang et al., 2020 | Aged male mice | 5 mg/kg into the abdomen every other day, three doses; measured 30 days later |
| Hu et al., 2025 | Aged mice | 5 mg/kg into the abdomen every 2 days for 4 weeks to 1 month |
| Meng et al., 2021 | Lung tumors and radiation lung injury in mice | 5 mg/kg into the abdomen on days 1, 3 and 5 of a week, for 2 cycles |
| Kong et al., 2025 | Keloid and skin fibroblasts | 25 µM for 3 days |
| Deryabin et al., 2022 | Endometrial stem cells | 25 µM for 3 days |
Every amount above is a mouse or cell amount. We found no human dose, and nobody has been dosed in a study. A per-kilogram mouse figure doesn’t convert to a person’s dose. Nothing here is a dosing recommendation, and we don’t repeat protocols or cycle lengths from seller or guide pages.
Side effects and safety
- In people. We found no study that gave FOXO4-DRI to people, so there are no human side-effect data, and a missing report of harm isn’t evidence of safety.
- Lungs. In mice prone to pulmonary hypertension, FOXO4-DRI or navitoclax was followed by changed lung blood pressure and loss of the cells lining lung blood vessels. The authors say eliminating senescent lung vessel cells may worsen lung blood pressure (Born et al., 2023). In two bleomycin mouse models the same peptide reduced scarring (Han et al., 2022; Liu et al., 2023).
- Heart and muscle. FOXO4 is made in human muscle, placenta and testis. The 2020 authors say muscle damage, especially heart damage, needs attention and that they could not test it (Zhang et al., 2020). In the 2017 mice, heart sections of treated animals showed no apparent abnormalities (Baar et al., 2017).
- Which cells it hits. In the lung fibrosis study the peptide preferentially killed myofibroblasts made with TGF-beta over ordinary lung fibroblast lines (Han et al., 2022), and in the endometrial stem cell study it didn’t single out senescent cells (Deryabin et al., 2022).
- Who paid and who gains. The 2017 paper says the peptide and mice are subject to patent applications; two authors co-founded companies the paper says were not involved. The 2020 testosterone paper and the 2025 keloid paper report no conflicts of interest (Baar et al., 2017; Zhang et al., 2020; Kong et al., 2025).
- Not known. Long-term safety, effects on the heart, cancer risk, reproduction, interactions, and what is in vials sold online. Side effects people report online aren’t covered here; they come from users, not studies.
Legal and approval status
- Not approved. We found no Drugs@FDA application for FOXO4-DRI (openFDA). The FDA’s drug listing directory has three bulk-ingredient listings named “FOXO4-DRI Synthetic Peptide”, 25 g of powder each, listed since September and October 2025. The active-ingredient field in all three names a cat-allergen peptide, not FOXO4-DRI. A listing isn’t an approval (openFDA NDC).
- Compounding. FOXO4-DRI isn’t named on the FDA’s page of bulk substances that may present significant safety risks, current as of April 22, 2026, or in its list of bulk substances nominated for compounding under section 503A, updated May 14, 2026 (FDA page; FDA document). We did not research whether pharmacies may lawfully compound it.
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides, not this one (Reuters, 2026).
- Other countries. We did not check how other countries regulate it.
- Sport. The World Anti-Doping Agency’s 2026 list, section S0, prohibits at all times any pharmacological substance with no current government approval for human therapeutic use that isn’t addressed elsewhere on the list. FOXO4-DRI isn’t named (WADA, 2026).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and from the FDA:
- “Clinical trials.” We found none registered, and none in PubMed. The results are from mice, rats and cells.
- “Only kills senescent cells.” That is the aim. In cell and mouse studies it worked in some settings, failed to single out senescent cells in one, and was followed by harm in a lung blood-pressure model.
- “Reverses aging.” The mouse results were fitness, fur and kidney markers, with no lifespan data. Fur photos are not evidence of benefit in people.
- “Dosing guide” and protocols. There is no human dose. The mouse amounts are per kilogram of a mouse, given three times.
- Which peptide. ES2, CPP-CAND and the shorter core fragments are different peptides, and the dasatinib-with-quercetin studies are not FOXO4-DRI studies.
- “Pure.” We found no analysis of vials sold online. Ask for a batch report that checks identity and purity.
- Competition. The 2026 WADA list bans unapproved substances under S0.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
Trials under way
We found no FOXO4-DRI trial that is recruiting or active, so there is nothing to list on our recruiting or in-progress pages. ClinicalTrials.gov searches on November 16, 2026 for FOXO4-DRI, FOXO4 DRI and Proxofim found no record (search). A search for FOXO4 alone returns one lymphoma trial that does not use the peptide (NCT07494565). A registry search isn’t proof that no unregistered study exists.
What’s still unknown
- Whether FOXO4-DRI does anything in people; we found no study that gave it to anyone.
- Whether the mouse lung, kidney and testosterone findings hold in people, and whether the lung harm does.
- What it does to the heart and muscle, which its authors could not test.
- Whether it picks out senescent cells in more tissues than the ones tested, given the endometrial result.
- Whether it extends life; we found no lifespan data.
- What is in FOXO4-DRI sold online; we found no analysis.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention FOXO4-DRI. We recheck every month. Last checked Nov 16, 2026.
We found no retracted, withdrawn or flagged studies that mention FOXO4-DRI.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Baar et al., 2017 | Cell | No retraction or concern |
| Zhang et al., 2020 | Aging (Albany NY) | No retraction or concern |
| Huang et al., 2021 | Front Bioeng Biotechnol | No retraction or concern |
| Le et al., 2021 | EBioMedicine | No retraction or concern |
| Meng et al., 2021 | JCI Insight | No retraction or concern |
| Han et al., 2022 | J Cell Mol Med | No retraction or concern |
| Deryabin et al., 2022 | Int J Mol Sci | No retraction or concern |
| Born et al., 2023 | Circulation | No retraction or concern |
| Liu et al., 2023 | Naunyn Schmiedebergs Arch Pharmacol | No retraction or concern |
| Jing et al., 2024 | Am J Respir Cell Mol Biol | No retraction or concern |
| Li et al., 2024 | Exp Gerontol | No retraction or concern |
| Kong et al., 2025 | Commun Biol | No retraction or concern |
| Bourgeois et al., 2025 | Nat Commun | No retraction or concern |
| Kang et al., 2025 | J Med Chem | No retraction or concern |
| Hu et al., 2025 | Front Bioeng Biotechnol | No retraction or concern |
| Alameen et al., 2026 | Naunyn Schmiedebergs Arch Pharmacol | No retraction or concern |
| Ning et al., 2026 | Mol Carcinog | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is FOXO4-DRI?
FOXO4-DRI is a lab-made peptide of 46 amino acids, built from D-amino acids in reverse order. It was designed to disrupt the binding of FOXO4 to p53 in senescent cells so that they die (Baar et al., 2017; PubChem).
What does FOXO4-DRI peptide do?
In senescent cells in a dish it made p53 leave the nucleus and triggered cell death. In mice it restored fitness, fur density and kidney markers. We found no study in people (Baar et al., 2017).
Is FOXO4-DRI safe?
Unknown in people: we found no human study. In mice prone to pulmonary hypertension it was followed by loss of lung blood-vessel cells, and its authors could not test heart and muscle damage (Born et al., 2023; Zhang et al., 2020).
What are the side effects of FOXO4-DRI?
We found no human side-effect data. Animal findings include changed lung blood pressure and loss of lung blood-vessel cells in a mouse model (Born et al., 2023).
Has FOXO4-DRI been tested in humans?
We found no study that gave it to people and no registered trial. Human cartilage, skin and endometrial cells have been treated in a dish (Huang et al., 2021; Kong et al., 2025; Deryabin et al., 2022).
What dose of FOXO4-DRI did the studies use?
Only mouse and cell amounts: 5 mg/kg three times in the 2017 mice, and 25 µM on cells. There is no human dose. See what the studies used. It is not a dosing recommendation (Baar et al., 2017).
What is a FOXO4-DRI protocol or cycle?
There is no tested human protocol. The mouse studies gave three doses every other day, or injections every two days for up to a month (Zhang et al., 2020; Hu et al., 2025).
Does FOXO4-DRI reverse aging?
In fast-aging and aged mice it restored fitness, fur density and kidney markers. The paper reports no lifespan data and no study in people (Baar et al., 2017).
Does FOXO4-DRI raise testosterone?
In aged male mice it did, 30 days after three doses. We found no study in people (Zhang et al., 2020).
What is Proxofim?
A name used for FOXO4-DRI on Wikipedia and in popular sources. We found no record of it in the FDA’s substance registry or its approved drugs.
Is FOXO4-DRI FDA-approved?
No. We found no Drugs@FDA application (openFDA).
Is FOXO4-DRI banned in sport?
It isn’t named on the 2026 WADA list. Its S0 class prohibits unapproved substances at all times (WADA, 2026).
What is the difference between FOXO4-DRI and dasatinib with quercetin?
They are different senolytics. Dasatinib with quercetin are small molecules; FOXO4-DRI is a peptide that blocks FOXO4 from p53. Results for one don’t carry to the other (Alameen et al., 2026).
Are there FOXO4-DRI clinical trials recruiting?
We found none. ClinicalTrials.gov has no record for FOXO4-DRI or Proxofim (search, November 16, 2026).
Sources
- Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. PubMed 28340339
- Zhang C, Xie Y, Chen H, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12(2):1272-1284. PubMed 31959736
- Li Y, Zhang C, Cheng H, et al. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Exp Gerontol. 2024;195:112522. PubMed 39025385
- Hu Z, Li F, Hu C, et al. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Front Bioeng Biotechnol. 2025;13:1729166. PubMed 41625068
- Han X, Yuan T, Zhang J, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med. 2022;26(11):3269-3280. PubMed 35510614
- Correction to “FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.” J Cell Mol Med. 2024;28(16):e18502. PubMed 39166551
- Liu Y, Hou Q, Wang R, et al. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(10):2393-2403. PubMed 37074394
- Meng J, Li Y, Wan C, et al. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis. JCI Insight. 2021;6(23):e146334. PubMed 34877934
- Jing X, Jia S, Teng M, et al. Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia. Am J Respir Cell Mol Biol. 2024;70(2):94-109. PubMed 37874230
- Born E, Lipskaia L, Breau M, et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023;147(8):650-666. PubMed 36515093
- Huang Y, He Y, Makarcyzk MJ, et al. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021;9:677576. PubMed 33996787
- Kong YX, Li ZS, Liu YB, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025;8(1):299. PubMed 39994346
- Deryabin PI, Shatrova AN, Borodkina AV. Targeting Multiple Homeostasis-Maintaining Systems by Ionophore Nigericin Is a Novel Approach for Senolysis. Int J Mol Sci. 2022;23(22):14251. PubMed 36430735
- Bourgeois B, Spreitzer E, Platero-Rochart D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16(1):5672. PubMed 40593617
- Kang D, Lim Y, Ahn D, et al. Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis. J Med Chem. 2025;68(15):15683-15694. PubMed 40739602
- Le HH, Cinaroglu SS, Manalo EC, et al. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine. 2021;73:103646. PubMed 34689087
- Ning N, Wang C, Gao T, et al. Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence. Mol Carcinog. 2026;65(9):1092-1104. PubMed 42391447
- Alameen AAM, Al-Kuraishy HM, Fawzy MN, et al. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(10):14659-14676. PubMed 42024235
- ClinicalTrials.gov. Searches for FOXO4-DRI, FOXO4 DRI and Proxofim, November 16, 2026: no record; a search for FOXO4 returns one lymphoma trial that does not use the peptide (NCT07494565). Search
- World Anti-Doping Agency. 2026 Prohibited List, section S0 (non-approved substances; FOXO4-DRI not named). WADA document
- U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for FOXO4-DRI and Proxofim found no application, November 16, 2026. openFDA
- U.S. Food and Drug Administration. openFDA drug listings (NDC): three bulk-ingredient listings named “FOXO4-DRI Synthetic Peptide” whose active-ingredient field names a cat-allergen peptide, November 16, 2026. openFDA NDC
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding (content current as of April 22, 2026; FOXO4-DRI not named). FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (FOXO4-DRI not named). FDA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- National Library of Medicine. PubChem compound record: FOXO4-DRI (a D-amino-acid peptide) (CID 168431240). PubChem
Last reviewed Nov 16, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.